EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders

EMA

28 October 2022 - EMA’s safety committee (PRAC) has recommended measures to minimise the risk of serious side effects associated with Janus kinase inhibitors used to treat several chronic inflammatory disorders. 

These side effects include cardiovascular conditions, blood clots, cancer and serious infections.

The Committee recommended that these medicines should be used in the following patients only if no suitable treatment alternatives are available: those aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer.

Read EMA press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Europe , Regulation , Safety